E
Unicycive Therapeutics, Inc. UNCY
$0.64 $0.000.00% NASDAQ
Recommendation
Prev Close
$0.64
Volume
229,272
Avg Vol (90D)
1,029,975
Market Cap
$76.61M
Dividend & Yield
--
52-Week Range
$0.202 - $1.29
P/E (TTM)
--
EPS (TTM)
-$0.8332
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Silverarc Capital Management LLC Has $1.98 Million Position in Unicycive Therapeutics, Inc. (NASDAQ:UNCY)
4/24/2025 - MarketBeat
Unicycive Therapeutics (NASDAQ:UNCY) Earns Buy Rating from Analysts at Guggenheim
4/24/2025 - Zolmax
Unicycive Therapeutics (NASDAQ:UNCY) Now Covered by Analysts at Guggenheim
4/23/2025 - MarketBeat
Unicycive Therapeutics (NASDAQ:UNCY) Now Covered by Analysts at Guggenheim
4/21/2025 - Ticker Report
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Shares Purchased by Vivo Capital LLC
4/21/2025 - Ticker Report
Unicycive Therapeutics initiated with a Buy at Guggenheim
4/21/2025 - TipRanks Financial Blog
Unicycive Therapeutics initiated with bullish view at Guggenheim
4/21/2025 - The Fly
HC Wainwright Reaffirms "Buy" Rating for Unicycive Therapeutics (NASDAQ:UNCY)
4/13/2025 - MarketBeat
Unicycive Presents New Patient-Level Data Underscoring Challenges Faced with Current Phosphate Binders and Highlighting the Potential of Oxylanthanum Carbonate to Address Barriers to Adherence for Patients with Hyperphosphatemia on Dialysis
4/10/2025 - Globe Newswire
Research Analysts Offer Predictions for UNCY FY2025 Earnings
4/6/2025 - MarketBeat
HC Wainwright Analysts Reduce Earnings Estimates for UNCY
4/6/2025 - MarketBeat
Brookline Capital Management Estimates UNCY Q1 Earnings
4/5/2025 - MarketBeat
HC Wainwright Increases Unicycive Therapeutics (NASDAQ:UNCY) Price Target to $7.50
4/2/2025 - MarketBeat
Unicycive Therapeutics (NASDAQ:UNCY) Posts Quarterly Earnings Results, Misses Estimates By $0.13 EPS
4/1/2025 - MarketBeat
Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
4/1/2025 - GuruFocus
We Think Unicycive Therapeutics (NASDAQ:UNCY) Needs To Drive Business Growth Carefully
4/1/2025 - Simply Wall St
Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
4/1/2025 - Globe Newswire
Unicycive Therapeutics price target raised by $3.50 at H.C. Wainwright, here's why
4/1/2025 - The Fly
Unicycive Therapeutics reports FY24 EPS (56c), consensus (51c)
3/31/2025 - TipRanks Financial Blog
Unicycive Therapeutics reports FY24 EPS (56c), consensus (51c)
3/31/2025 - The Fly
Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update
3/31/2025 - GuruFocus
Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update
3/31/2025 - Globe Newswire
DaVita Stock Declines 1.2% in 3 Months: Here's How to Play
3/26/2025 - Zacks Investment Research
Unicycive Therapeutics (UNCY) Projected to Post Quarterly Earnings on Thursday
3/20/2025 - MarketBeat
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest Update
3/15/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$32.10M
EBIT (TTM)
-$32.12M
Net Income (TTM)
-$36.73M
Balance Sheet
Total Assets (Q)
$31.67M
Total Debt (Q)
$681.00K
Total Liabilities (Q)
$24.24M
Book Value Per Share (Q)
$0.0653
Cash Flow
Cash from Operations (TTM)
-$28.58M
Cash from Investing (TTM)
-$72.00K
Cash from Financing (TTM)
$45.09M
Net Change in Cash (TTM)
$16.44M
Filings
Filing Date
Monday, March 31, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 12 and 16 (est)
Price History
Loading...
Beta
1.50
7-Day Total Return
7.02%
30-Day Total Return
9.40%
60-Day Total Return
10.34%
90-Day Total Return
-10.43%
Year to Date Total Return
-19.23%
1-Year Total Return
-37.86%
2-Year Total Return
-52.94%
3-Year Total Return
-35.95%
5-Year Total Return
--
52-week Low
Aug 13, 2024 - $0.202
52-week High
Apr 29, 2024 - $1.29
Valuation
Market Cap
$76.61M - Micro Cap
Enterprise Value
$51.15M
Price/Sales (TTM)
--
Price/Book (Q)
9.80
Dividends and Shares
Shares Outstanding
105.72M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
unicycive.com
Phone Number
650 351 4495
Address
4300 El Camino Real
Los Altos, CA 94022
Country
United States
Year Founded
2016
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that... more
NASDAQ 04/25/2025 4:00PM Eastern Quotes delayed